Loading...

ADAP ADAPTIMMUNE THERAPEUTICS PLC Disposals and divestitures 8-K Filing

DPTM

DP

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)

2025 8-K

Show Summary

Summary

Divestment of Assets

Asset Acquisitions

Financial Statements

Transfer of Listing

Management Change

Loan Agreement Amendment

Financial Update

Management Changes

Workforce Reduction

Trial Data Announcement

Nasdaq Compliance

Collaboration Termination

Q2 Financial Results

FDA Approval of TECELRA

Amended Severance Policy

Executive Severance Policy

Clinical Collaboration Agre...

Financial Results

Annual General Meeting

Termination of Agreement

Financial Results Announcement

Appointment of Chief Commer...

FDA Accepts Adaptimmune's B...

Adaptimmune Therapeutics Pl...

Submission of Biologics Lic...

Amendment to Annual Report

Financial Results Announcement

Resignation of Director

Delisting Notice

Financial Results Announcement

Amendments to Share Option ...

Completion of Merger

Shareholder Meeting Approval

Merger Agreement

Annual General Meeting

Financial Results and Corpo...

Termination and Transfer Ag...

Regulatory Disclosure

Termination, Financial Resu...

Merger Agreement

Appointment and Resignation

Termination of Material Def...

External Links:

On July 31, 2025, Adaptimmune Therapeutics PLC paid approximately $29.1 million to Hercules Capital to settle its debt and completed the sale of its TECELRA and related therapies to USWM CT, LLC, marking a significant asset divestiture. This event reflects a strategic shift and has implications for Adaptimmune's financial position going forward.

AI Assistant

ADAPTIMMUNE THERAPEUTICS PLC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.